+6.2%
GSK vs ALHC
-58.1%
+64.3%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | ALHC | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -11.8% | +10.5% | -0.9% |
| 7D | -3.1% | -12.6% | +9.5% | -2.7% |
| 30D | -0.9% | -20.0% | +19.1% | -0.2% |
| 3M | -4.2% | -49.2% | +45.0% | -2.1% |
| 6M | -1.6% | -58.7% | +57.1% | +0.1% |
| YTD | +2.6% | -66.0% | +68.6% | +2.3% |
| 1Y | +6.2% | -58.3% | +64.5% | +3.3% |
| All | +6.2% | -58.1% | +64.3% | +3.3% |
Cumulative growth
Daily Returns
Daily percentage return beside ALHC.
Daily Out/Under-Performance
Portfolio return minus ALHC return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × ALHC return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded ALHC wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling